Turning Microbes into Cancer Therapeutics

We believe the best science happens in environments built on curiosity, collaboration, and trust.

Lets talk

WHY CANCERS PERSIST

Cancers evade the immune system

Tumors often develop ways to hide from or suppress the immune system, limiting the effectiveness of many current immunotherapies. While treatments like checkpoint inhibitors, T cell engagers, and engineered T-cell therapies have transformed care for some patients, many cancers remain resistant including high-risk leukemias like AML , soft-tissue sarcomas, and many solid tumors.

Tumors suppress the immune system and evade detection

Most antibody therapies only work for a subset of patients

Cell therapies can be complex and difficult to scale

SOLVING IMMUNE EVASION

The QUAIL Platform

The QUAIL platform was designed to overcome these challenges by activating a powerful innate immune response inside the body. Built on highly attenuated microbial vectors, the platform engages key immune pathways in vivo to drive anti-tumor activity in AML, other high-risk leukemias and soft-tissue sarcomas. By stimulating innate T cell populations and enhancing immune recognition, the QUAIL platform enables robust and durable activation and expansion of endogenous innate T cells .

Engineered microbe

Activation of innate T cells

Immune attack on tumors

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

Laguna’s platforms specifically activate and expand innate T cells including γδ T cells, MAIT cells, and NK T cells. These unconventional T cells are uniquely capable of recognizing and eliminating cancers as well as orchestrating comprehensive immune responses.

In Vivo Immunotherapy

Laguna’s platforms activate immune responses directly inside the body and direct them to target cells. This achieves the ideal goals of in vitro CAR-T therapies without the complexity or risks associated with immune cell engineering.

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

In Vivo Immunotherapy

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

In Vivo Immunotherapy

Pipeline

Our pipeline applies the QUAIL and IBIS Platforms across multiple cancer settings

Hematologic Programs

LGNA 100 / 200

AML, Multiple Myeloma

Solid Tumor Programs

LGNA 200 / 300

Sarcoma, Colorectal Cancer

Platform Expansion

LGNA 400+

Solid Tumor Indications, Inflammatory + Infectious Diseases

Our Partners

REIMAGINING IMMUNOTHERAPY

Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.

Laguna is a biotechnology company developing next-generation microbial platforms designed to activate innate immune responses against cancer. By combining insights from microbiology and immunology, the company is building a new class of immunotherapies designed to be safer, scalable, and effective across multiple cancer types.

REIMAGINING IMMUNOTHERAPY

Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.

REIMAGINING IMMUNOTHERAPY

Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.